What question did this study set out to answer?

This research aims to assess the effectiveness of switching treatments from belimumab to telitacicept in managing lupus nephritis.

March 28, 2026Open Access

Wcn26-3956 Successful Treatment of Lupus Nephritis by Switching From Belimumab to Telitacicept: A Case Analysis

Key Points

This research aims to assess the effectiveness of switching treatments from belimumab to telitacicept in managing lupus nephritis.
Analyzed 85 survivors with lupus nephritis treatment history.
Assessed kidney function over a median follow-up of 8.9 years.
Constructed Kaplan-Meier curves for CKD development among treatment groups.
No significant differences found in CKD development between certain treatment groups.
AKI did not significantly predict the risk for CKD based on statistical analysis.
All patients maintained kidney function without needing replacement therapy.

Abstract

Results:The 85 survivors had a median age of 6.4 years at initiating treatment, including 30 girls, and were studied for a median of 8.9 years.Forty-six patients developed AKI and 20 developed CKD.No patients required kidney replacement therapy.There were 31, 34, 8, and 12 patients in Groups 1 to 4, respectively.The Figure shows the 5-year changes in the mean Cr-eGFR in each group.Kaplan-Meier curves for the development of CKD were constructed for the four groups, and the Logrank test revealed no significant differences between Groups 1 and 2, whereas a significant difference was observed between Groups 3 and 4. In contrast, in the univariate Cox proportional hazards model, AKI was not a significant risk factor for CKD (hazard ratios HR 1.455, 95% confidence interval CI: 0.594-3.564,p = 0.412).In a subanalysis, we

Bookmark

View Full Paper

Cite This Study

Lv et al. (Wed,) studied this question.

synapsesocial.com/papers/69c770888bbfbc51511e0929 https://doi.org/https://doi.org/10.1016/j.ekir.2026.105737

Bookmark

View Full Paper